Dr. Joy currently serves as a Professor of Oncology. Division of Medical Oncology, Faculty of Medicine and Dentistry at the University of Alberta and also as a staff Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta.
He received his Bachelor of Science Degree (Honours with Distinction, Specialization in Pharmacology) and Medical Doctorate (Honours with Distinction) from the University of Alberta. He is certified by the Royal College of Physicians and Surgeons of Canada as a specialist in Internal Medicine with sub-specialty certification in Medical Oncology.
Dr. Joy was awarded with a Future Leaders of Oncology (FLO) award in 2011 and has since completed and obtained 8 Certificates of Achievement within the Physician Management Institute (PMI) - Canadian Medical Association. He was also chosen and completed the inaugural Academic Leadership Development Program at University of Alberta in 2013.
His primary oncologic care interests include Breast and Thoracic malignancies.
He is actively involved in patient care, clinical research, medical education, cancer survivorship / well-being, cancer advocacy and global/regional oncology disparity issues and has peer-reviewed publications in these areas.
He is involved in numerous local, university, provincial and national committees. He has served as a medical advisor to both the Comprehensive Breast Care Program (Edmonton) and the Hereditary Breast and Ovarian Cancer Society (Alberta). He is a Scientific Advisory Council member to Rethink Breast Cancer and serves on the Wellspring Healthcare Advisory Committee (Edmonton).
He is actively involved with the Canadian Clinical Trials Group, and serves as National Chair for the CCTG MA.38 metastatic breast cancer clinical trial.
His former appointments include serving on the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer, past Chair of the Northern Alberta Breast Cancer Program, Medical Director (Edmonton) of the Alberta Cancer Research Biobank (former CBCF Tumor Bank), pan-Canadian Working Group on Primary Care and Oncology Care Integration (Canadian Partnership Against Cancer) as well as Provincial Chair of the Alberta Breast Cancer Program.
Most recently, he was appointed to the pan-Canadian Oncology Drug Review (pCODR) Canadian Agency for Drugs and Technologies in Health (CADTH) where he serves on the Expert Review Committee (pERC) where they assess the clinical evidence and cost-effectiveness of cancer drugs in order to make recommendations to help guide drug funding decisions across Canada.
- Phase II / III Clinical Trials – Breast and Thoracic Malignancies
- Cancer Biology, Exercise–Cardiovascular–Oncology Research, REthining Clinical Trials (REaCT)
- Hereditary Breast Cancer, Breast Cancer in Young Women, Cancer Survivorship
- Oncology Drug Approval, Cancer Guideline Development
- Global Oncology and Regional Disparity Issues
- Medical / Public Education